Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Lion’s Mane is the latest standout in functional food & beverages | Food Dive (opens in a new tab)

fooddive.com · 2025-06-30

Short answerEvidenceSource

Short answer

Not supported

Not supported.

One key claim is not backed by the study.

  • 3 overstated
  • 1 not supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Four claims go beyond the study. Three overstate it and one isn't supported at all.

  • 3 overstated
  • 1 not supported
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not supportedThe debut of Applied Food Sciences’ MycoThrive™ Lion’s Mane is described as being featured alongside a clinical study demonstrating the ingredient’s ability to improve daily focus and mood, and the article calls it a first-of-its-kind study on the acute effects of lion’s mane in healthy adults.View evidenceHide evidence

As statedwithin an hour of consumption

Why this verdict

The supplied paper profile does not identify MycoThrive™ as the tested ingredient, and it does not show Lion’s Mane improving “daily focus and mood” as stated. For Lion’s Mane, the abstract-level evidence is limited to selected objective task metrics and happiness-related subjective items; focus/mood improvements are reported primarily for guayusa, not Lion’s Mane. The “first-of-its-kind” characterization is also not substantiated by the supplied abstract profile.

1

Study evidence

AMT (650 mg) significantly improved Serial 7s performance (number of attempts) compared with baseline/placebo (p ≤ 0.05).

“Using a randomized, double-blind, placebo-controlled, crossover design”
2

Study evidence

Guayusa extract (AMT, 650 mg) significantly improved self-reported mental clarity, focus, concentration, mood, and productivity at 1 and 2 hours post-ingestion and improved stress tolerance at 1 hour; AMT ratings were greater than those for Lion's Mane and placebo on mental clarity, focus, concentration, and productivity (abstract-reported).

“subjective assessments of cognitive perception”
Claim 2 of 4OverstatedLion’s mane is presented as a functional mushroom with a growing list of cognitive and emotional health benefits, and is described as the “smart mushroom.”View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports only specific acute findings for 1 g Nordic Lion’s Mane in a single-dose crossover trial: limited objective cognitive-task changes and certain happiness-related self-ratings. The story’s broad, unhedged framing that lion’s mane offers a “growing list” of cognitive and emotional health benefits and is the “smart mushroom” generalizes beyond the profiled evidence.

1

Study evidence

AMT (650 mg) significantly improved Serial 7s performance (number of attempts) compared with baseline/placebo (p ≤ 0.05).

“Using a randomized, double-blind, placebo-controlled, crossover design”
2

Study evidence

Guayusa extract (AMT, 650 mg) significantly improved self-reported mental clarity, focus, concentration, mood, and productivity at 1 and 2 hours post-ingestion and improved stress tolerance at 1 hour; AMT ratings were greater than those for Lion's Mane and placebo on mental clarity, focus, concentration, and productivity (abstract-reported).

“subjective assessments of cognitive perception”
Claim 3 of 4OverstatedThe article says lion’s mane has clinically shown it can enhance memory, focus, and mental clarity, and that recent studies show it can acutely elevate mood and feelings of happiness in as little as an hour after ingestion.View evidenceHide evidence

As statedin as little as an hour after ingestion

Why this verdict

The trial profile reports statistically significant but selective Lion’s Mane effects on Serial 7s attempts, N-Back reaction time, Go reaction time, and some happiness-related ratings. It does not support the broad unhedged claim that lion’s mane clinically enhances memory, focus, and mental clarity, nor that it acutely elevates mood broadly. Some 1-hour happiness-related effects are consistent with the abstract, but the overall causal claim outruns the specific outcomes and timing reported.

1

Study evidence

AMT (650 mg) significantly improved Serial 7s performance (number of attempts) compared with baseline/placebo (p ≤ 0.05).

“Using a randomized, double-blind, placebo-controlled, crossover design”
2

Study evidence

Guayusa extract (AMT, 650 mg) significantly improved self-reported mental clarity, focus, concentration, mood, and productivity at 1 and 2 hours post-ingestion and improved stress tolerance at 1 hour; AMT ratings were greater than those for Lion's Mane and placebo on mental clarity, focus, concentration, and productivity (abstract-reported).

“subjective assessments of cognitive perception”
Claim 4 of 4OverstatedThe article further claims MycoThrive™ Lion’s Mane showed significant acute results for improved focus, memory, and mood within an hour of consumption.View evidenceHide evidence

As statedwithin an hour of consumption

Why this verdict

The abstract profile supports some statistically significant acute Lion’s Mane results, but not the story’s combined claim that MycoThrive™ improved focus, memory, and mood within an hour. The product identity is not verifiable from the supplied profile, Lion’s Mane effects were selective, and timing for objective outcomes is not fully disaggregated in the abstract, with some Lion’s Mane effects described at 2 hours rather than clearly within 1 hour.

1

Study evidence

AMT (650 mg) significantly improved Serial 7s performance (number of attempts) compared with baseline/placebo (p ≤ 0.05).

“Using a randomized, double-blind, placebo-controlled, crossover design”
2

Study evidence

Guayusa extract (AMT, 650 mg) significantly improved self-reported mental clarity, focus, concentration, mood, and productivity at 1 and 2 hours post-ingestion and improved stress tolerance at 1 hour; AMT ratings were greater than those for Lion's Mane and placebo on mental clarity, focus, concentration, and productivity (abstract-reported).

“subjective assessments of cognitive perception”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper was a randomized, double-blind, placebo-controlled crossover trial comparing single-dose guayusa extract, 1 g Nordic Lion’s Mane, and placebo over 1–2 hours.

    The story mentions a clinical study but, based on the presentation, does not convey key design features, comparators, dose, crossover structure, or the fact that guayusa—not just Lion’s Mane—was central to the trial.

    From Randomized double-blind placebo-controlled crossover; randomized double-blind placebo-controlled crossover; Randomized d

  • Lion’s Mane objective cognitive findings were limited to selected task metrics: Serial 7s attempts, N-Back reaction time, and Go reaction time.

    The story frames the findings as broader improvements in focus, memory, and mental clarity. The abstract profile supports narrower task-specific effects and provides no effect sizes or clinical magnitude.

    From Randomized double-blind placebo-controlled crossover

  • Subjective benefits differed by ingredient: guayusa improved self-reported mental clarity, focus, concentration, mood, and productivity; Lion’s Mane improved certain happiness-related ratings.

    The story attributes focus and mood improvements to Lion’s Mane/MycoThrive, but the paper profile assigns those broader subjective focus/mood effects primarily to guayusa. Lion’s Mane support is narrower, involving happiness-related items.

    From randomized double-blind placebo-controlled crossover

  • Placebo also showed improvement from baseline in self-reported focus and concentration at 1 hour.

    This is an interpretation-changing detail because it tempers claims about subjective focus/concentration changes, but it is not included in the story caveats.

    From randomized double-blind placebo-controlled crossover

  • The abstract does not report sample size, participant demographics, effect sizes, confidence intervals, or detailed clinical magnitude.

    The story’s caveats focus on ingredient vetting and product quality, not on the study-reporting limitations that restrict how strongly the results can be interpreted.

    From Randomized double-blind placebo-controlled crossover; randomized double-blind placebo-controlled crossover; Randomized d

  • The study assessed acute single-dose effects over only a 2-hour window, not sustained daily benefits or long-term cognitive/emotional health outcomes.

    The story uses language such as daily focus and broad cognitive/emotional benefits, while the supplied paper profile supports only short-term acute measurements after one dose.

    From Randomized double-blind placebo-controlled crossover; randomized double-blind placebo-controlled crossover

  • Guayusa uniquely elevated blood pressure from baseline in the trial.

    This safety/physiology finding is part of the paper profile but is not reflected in the story presentation. It is less central to Lion’s Mane efficacy claims, but it matters for accurately representing the overall study context and comparator ingredient.

    From Randomized double-blind placebo-controlled crossover

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine acute effects of a single dose of guayusa extract (AmaTea® Max) versus Nordic Lion’s Mane extract versus placebo on objective cognitive task performance over 2 hours in a randomized, double-blind, placebo-controlled crossover study.Randomized double-blind placebo-controlled crossoverExpand

In plain English

Randomized, double-blind, placebo-controlled crossover trial evaluated acute (1 and 2 h post-dose) effects of a single oral dose of 650 mg guayusa extract (AmaTea® Max, AMT) versus 1 g Nordic Lion's Mane (LM) versus placebo on objective cognitive task performance (Go/No-go, N-Back, Serial 7s). AMT produced multiple statistically significant improvements across Serial 7s and N-Back outcomes and faster Go stimulus reaction time but reduced No-go accuracy; LM produced more limited improvements (Serial 7s attempts, N-Back reaction time, Go stimulus reaction time). Results reported as p ≤ 0.05 (no effect sizes reported in the abstract).

Key findings

  • AMT (650 mg) significantly improved Serial 7s performance (number of attempts) compared with baseline/placebo (p ≤ 0.05).
  • AMT significantly improved multiple N-Back outcomes: total score, number of correct responses, total number of responses, and reaction time (p ≤ 0.05).
“Using a randomized, double-blind, placebo-controlled, crossover design”
What this piece can’t prove
  • Abstract does not report sample size, participant demographics, or detailed statistical estimates (effect sizes, confidence intervals).

2 further details could not be confirmed from the summary.

2human in vivoDetermine acute effects of guayusa extract versus Lion’s Mane versus placebo on subjective self-perceived cognitive/affective ratings over 2 hours in the same crossover study.randomized double-blind placebo-controlled crossoverExpand

In plain English

In a randomized, double-blind, placebo-controlled crossover trial testing single oral doses (650 mg guayusa extract [AmaTea® Max], 1 g Nordic Lion's Mane, and placebo) with repeated assessments at baseline, 1 h, and 2 h, guayusa (AMT) produced statistically significant improvements in multiple self-reported cognitive/affective ratings (mental clarity, focus, concentration, mood, productivity) at 1 and 2 h and increased ability to tolerate stress at 1 h. Lion's Mane (LM) and AMT both improved certain happiness-related items ("happiness compared to peers" and "getting the most out of everything"), with LM showing earlier effects (noted at 1 h). Placebo showed small improvements in focus and concentration at 1 h from baseline. The abstract reports group/time comparisons and significance (p≤0.05 or p<0.05) but does not provide scale names, numerical effect sizes, or sample details in the abstract.

Key findings

  • Guayusa extract (AMT, 650 mg) significantly improved self-reported mental clarity, focus, concentration, mood, and productivity at 1 and 2 hours post-ingestion and improved stress tolerance at 1 hour; AMT ratings were greater than those for Lion's Mane and placebo on mental clarity, focus, concentration, and productivity (abstract-reported).
  • Lion's Mane (1 g) improved certain subjective happiness-related ratings ("happiness compared to peers" and "getting the most out of everything"), with earlier effects observed at 1 hour; AMT also improved these happiness items but was reported at 2 hours.
“subjective assessments of cognitive perception”
What this piece can’t prove
  • Abstract does not report sample size, participant demographics, or eligibility criteria.

4 further details could not be confirmed from the summary.

3human in vivoAssess acute effects of guayusa extract and Lion’s Mane versus placebo on vital signs (notably blood pressure) over 2 hours in the same crossover study.Randomized double-blind placebo-controlled crossoverExpand

In plain English

In the randomized, double-blind, placebo-controlled crossover trial, acute single-dose ingestion of AmaTea® Max guayusa extract (650 mg) was associated with an elevation in blood pressure from baseline within the 2-hour post-dose assessment window; this effect was reported as unique to the guayusa condition in the abstract. Vital signs were measured at baseline, 1 h, and 2 h post-ingestion. No numeric BP values, effect sizes, or detailed timing/magnitude are reported in the abstract.

Key findings

  • AmaTea® Max guayusa extract (650 mg) was reported to uniquely elevate blood pressure from baseline within the 2-hour post-dose assessment window.
“vital signs”
What this piece can’t prove
  • Acute single-dose effects over 2 hours may not reflect longer-term safety or repeated dosing effects.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

And 28 more candidates considered.